Owkin Achieves Milestone with First Patient Dosed in AI-Optimized Phase I Trial of OKN4395, a First-in-Class Triple Inhibitor for Solid Tumors On January 22, 2025, Owkin, the pioneering end-to-end AI biotech company transforming drug discovery, development, and diagnostics through agent-based…
Biologics Market 2024-2030: Global Industry Poised to Reach $732.4 Billion – Trends, Drivers, and Key Insights The global biologics market is experiencing unprecedented growth, with its value estimated at $421.1 billion in 2023 and projected to reach $732.4 billion by…
Medicare Drug Price Negotiation Program Sparks Concerns Over Pharmacy Viability and Patient Access The National Community Pharmacists Association (NCPA) has issued an urgent call for the immediate suspension of the Medicare Drug Price Negotiation Program (MDPNP), citing its potential to…
Revolutionizing Clinical Development: Science Exchange Launches Cutting-Edge Supplier Orchestration Solution In today’s rapidly evolving life sciences landscape, clinical development teams face mounting pressure to manage increasingly complex outsourcing arrangements. From functional service provider (FSP) models to full-service outsourcing (FSO), the…
The “Biological Drugs – Global Strategic Business Report” has been added to ResearchAndMarkets.com’s offerings, providing an in-depth analysis of the market’s current landscape, trends, and future projections. The global biological drugs market was valued at approximately USD 345.3 billion in…
Photonic Inc. Founder Dr. Stephanie Simmons to Speak at UNESCO’s International Year of Quantum Science and Technology Opening Ceremony Paris, France – February 4-5, 2025 – Photonic Inc., a global leader in distributed quantum computing using silicon-based technologies, has announced…
European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP), the EU has approved Sarclisa in combination with a standard-of-care regimen—bortezomib, lenalidomide, and dexamethasone (VRd)—for the treatment of adult patients with newly diagnosed multiple myeloma (NDMM) ineligible for…
Two groundbreaking studies conducted by researchers at Washington University School of Medicine in St. Louis have identified a promising approach to halting the progression of several forms of blood cancer using a drug currently in clinical trials for breast cancer.…
Impact on WuXi AppTec’s Operations WuXi AppTec, a global leader in providing comprehensive R&D and manufacturing services for the pharmaceutical and life sciences industries, recently announced the signing of a definitive agreement to sell its U.S. medical device testing operations…
Biomedical Neuraly & Enigma Biomedical USA Partner on PET Imaging Biomarker PMI04 Neuraly, a biotechnology company specializing in the development of innovative treatments for neurodegenerative diseases, has entered into a research license and commercialization option agreement with Enigma Biomedical USA…
Pheno Therapeutics Receives Clinical Trial Authorization for MS Candidate PTD802 Pheno Therapeutics Limited, a leading biotechnology company focused on developing small molecule therapeutics for neurological diseases, has received Clinical Trial Authorisation (CTA) from the UK’s Medicines and Healthcare products Regulatory…
First Participants Enrolled in AskBio Phase II Gene Therapy Trial for Parkinson’s Disease AskBio Inc., a leading gene therapy company and a subsidiary of Bayer AG, announced today that the first participants have been successfully randomized in its Phase II…